<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703339</url>
  </required_header>
  <id_info>
    <org_study_id>TREINH-IPF-201</org_study_id>
    <nct_id>NCT00703339</nct_id>
  </id_info>
  <brief_title>Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Single-Dose, Dose-Escalating Study Exploring the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Inhaled Treprostinil Sodium Using the Nebu-Tec OPTINEB Inhalation Device in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lung Biotechnology PBC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lung Biotechnology PBC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish single-dose tolerability of inhaled treprostinil
      sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to
      explore the acute hemodynamic effects over a range of tolerable doses. The safety and
      pharmacodynamic information obtained from this study will inform the design and conduct of
      future studies in inhaled treprostinil sodium in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is Phase 2, multi-center, open-label, four-cohort study in subjects with pulmonary
      hypertension (PH) associated with idiopathic pulmonary fibrosis (IPF). Each cohort of four
      subjects will receive a single dose of inhaled treprostinil sodium. Cohorts will be enrolled
      sequentially, starting with the lowest dose of 18 mcg. Each cohort escalate by 18 mcg
      increments, resulting in four cohorts of 18, 36, 54, and 72 mcg doses. Decisions to escalate
      to the next dose cohort will be based upon the data from the previous completed lower dose
      cohort of four subjects. Approximately 16 subjects are expected to receive study drug,and
      approximately four center in the United States with expertise in IPF will participate in this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment to the trial. Very difficult population to recruit.
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Inhaled Treprostinil Sodium in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis,Reported as Number of Participants With Adverse Events</measure>
    <time_frame>3-5 days</time_frame>
    <description>Safety and Tolerability evaluation include any observed or reported changes in vital signs, ECGs, clinical chemistry ,hematological or urinalysis, and any reported symptoms following a single dose administration on the day of dosing and up to the final visit 3-5 days later. Adverse events will be tabulated by total incidence and by individual patient, and the severity, causality and outcomes will also be documented. Each cohort of 4 patients will be fully evaluated as described before proceeding to the escalation to the next dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters After a Single Dose of Inhaled Treprostinil and Acute Hemodynamic Effects.</measure>
    <time_frame>acute</time_frame>
    <description>PK samples will be collected at frequent intervals up to 4 hours following single dosing . Hemodynamic parameters at 4 hours post dosing include heart rate, pulmonary arterial pressure, systemic arterial pressure, right atrial pressure, pulmonary capillary wedge pressure, mixed venous oxygen saturation and cardiac output.</description>
  </secondary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treprostinil sodium for inhalation</intervention_name>
    <description>Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose
Dose:
Cohort 1: dosed at 3 breaths (18 mcg)
Cohort 2: dosed at 6 breaths (36 mcg)
Cohort 3: dosed at 9 breaths (54 mcg)
Cohort 4: dosed at 12 breaths (72 mcg)
The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  35 to 80 years of age

          -  Male or female

          -  Diagnosis of IPF

               1. Investigator diagnosis based on history, physical examination, HRCT,and pulmonary
                  function testing

               2. Clinical symptoms of IPF for at least three months prior to Visit 1

               3. High Resolution CT scan showing definite or probable IPF (any time in the past).
                  Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT
                  scan must also be present (at any time in the past)

               4. Surgical lung biopsy showing usual interstitial pneumonia, or transbronchial lung
                  biopsy that was not diagnostic of an alternative condition. For patients younger
                  than 50 years, a surgical lung biopsy is required (at any time in the past)

               5. FVC ≥ 30 % and &lt; 70% of predicted value within three months prior to Visit 1

               6. DLCO ≥ 15% and &lt;70% of predicted value within three months prior to Visit 1.

          -  Diagnosis of PH

               1. Previously documented radiographic or echocardiographic findings suggestive of
                  pulmonary hypertension

               2. Prior right heart catheterization diagnostic of pre-capillary pulmonary
                  hypertension. [The presence of pre-capillary pulmonary hypertension will be
                  verified by right heart catheterization during Study Visit 3, before enrollment
                  and administration of study drug].

          -  No changes in concomitant medications prescribed to treat PAH or IPF for 30 days to
             Visit 1

          -  Females of childbearing potential may participate only if they are not currently
             pregnant or lactating and are either one of the following:

               1. Surgically sterile

               2. At least 1 year post-menopausal

               3. Practicing an acceptable method of birth control for at least 30 prior to the
                  Visit 1 with plans to continue this method for the duration of their
                  participation in the study.

          -  An echocardiogram will be performed at Visit 2. Only those subjects with Visit 2
             echocardiographic findings that strongly suggest the presence of pulmonary
             hypertension, will proceed to Visit 3. Acceptable findings include any of the
             following:

               1. TR velocity greater than 3.5 m/sec

               2. TR velocity greater than 3.0 m/sec with right ventricular enlargement or
                  dysfunction

          -  A right heart catheterization will be performed at Visit 3. Only those subjects with
             Visit 3 right heart catheterization findings that establish the presence of pulmonary
             hypertension will proceed to enrollment and study drug administration. Acceptable
             findings must include all of the followings:

               1. mean PA pressure equal or greater than 25 mm HG

               2. pulmonary capillary wedge pressure equal or less than 15 mm Hg

               3. pulmonary vascular resistance greater than 3 mmHg/min

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if ANY of the following criteria
        apply:

          -  History of known or suspected pulmonary embolism or deep venous thrombosis

          -  Clinical evidence of left-sided heart disease

          -  Presence of atrial fibrillation (determined from 12 lead ECG at Visit 1 or 2)

          -  Other medical condition or drug exposure known to be associated with pulmonary
             fibrosis (e.g., rheumatoid arthritis, lupus, scleroderma, etc.) or pulmonary arterial
             hypertension (e.g., connective tissue disease, congenital heart disease, portal
             hypertension, HIV infection, drug and toxins, etc.)

          -  Upper or lower respiratory infection within 30 days prior to Visit 1

          -  Hospitalization for respiratory illness within 30 days prior to Visit 1

          -  Diagnosis of any other clinically significant illness that, in the opinion of the
             investigator, might put the subject at risk of harm from participation in the study or
             might adversely effect the interpretation of the study data. (e.g., significant liver
             or kidney disease, etc.)

          -  History of recurrent symptoms that might, in the opinion of the investigator,
             adversely effect the interpretation of the study data (e.g., severe headaches,
             diarrhea, jaw pain, syncope, nausea,vomiting, etc.)

          -  Current treatment with any medication that is approved by the US FDA to treat
             pulmonary hypertension (e.g., epoprostenol(Flolan), treprostinil (Remodulin), iloprost
             (Ventavis), bosentan(Tracleer), ambrisentan (Letairis), sildenafil (Revatio), etc.,),
             or tadalafil (Cialis)

          -  Current treatment with an anticoagulant

          -  A reactive screen for hepatitis B surface antigen, or the hepatitis C antibody, or HIV
             antibody as tested at Visit 1.

          -  Use of any inhaled tobacco products or significant history of drug abuse within 90
             days prior to Visit 1

          -  The subject has an echocardiogram performed at Visit 2 that demonstrate findings that
             are indicative of left ventricular or valvular disease. Findings that will be
             considered evidence of left ventricular or valvular disease, and therefore exclude the
             subject from proceeding to Visit 3 are any of the following:

               1. LVEF &lt; 55%

               2. Moderate to Severe mitral regurgitation or aortic regurgitation

               3. Any mitral stenosis or aortic stenosis

               4. Grade 2 or 3 diastolic dysfunction by Doppler

          -  Use of any investigational drug, or participation in any investigational study within
             the 30 days prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Medical Center m/c7381</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center/Advanced Lung Disease and LungTransplant Program</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5853</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTWS Medical Center Dallas/St. Paul Univ. Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <results_first_submitted>February 25, 2011</results_first_submitted>
  <results_first_submitted_qc>April 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2012</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrosis, pulmonary</keyword>
  <keyword>hypertension, pulmonary</keyword>
  <keyword>exercise, aerobic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>18mcg Inhaled Treprostinil Cohort</title>
          <description>Patients are to be divided in four cohorts of four patients each. The first cohort will receive a single dose of inhaled Treprostinil (18ug) and each subsequent cohort will receive increasing single doses of 36, 54 and 72ug.
Each patient will be evaluated on a screening visit (Visit 1) within 28 days prior to dosing, a confirmatory visit (Visit 2) within 14 days prior to dosing, a Baseline/Treatment/Post-Treatment visit( Visit 3) on the dosing day and a Follow-up Period (visit 4) for up to 5 days after dosing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>18mcg Inhaled Treprostinil Cohort</title>
          <description>Patients are to be divided in four cohorts of four patients each. The first cohort will receive a single dose of inhaled Treprostinil (18ug) and each subsequent cohort will receive increasing single doses of 36, 54 and 72ug.
Each patient will be evaluated on a screening visit (Visit 1) within 28 days prior to dosing, a confirmatory visit (Visit 2) within 14 days prior to dosing, a Baseline/Treatment/Post-Treatment visit( Visit 3) on the dosing day and a Follow-up Period (visit 4) for up to 5 days after dosing.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Inhaled Treprostinil Sodium in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis,Reported as Number of Participants With Adverse Events</title>
        <description>Safety and Tolerability evaluation include any observed or reported changes in vital signs, ECGs, clinical chemistry ,hematological or urinalysis, and any reported symptoms following a single dose administration on the day of dosing and up to the final visit 3-5 days later. Adverse events will be tabulated by total incidence and by individual patient, and the severity, causality and outcomes will also be documented. Each cohort of 4 patients will be fully evaluated as described before proceeding to the escalation to the next dose.</description>
        <time_frame>3-5 days</time_frame>
        <population>Insufficient enrollment, therefore no Participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>18mcg Inhaled Treprostinil Cohort</title>
            <description>Number of participates on a dose of three 6mcg breaths (18mcg total)with Adverse Events</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Inhaled Treprostinil Sodium in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis,Reported as Number of Participants With Adverse Events</title>
          <description>Safety and Tolerability evaluation include any observed or reported changes in vital signs, ECGs, clinical chemistry ,hematological or urinalysis, and any reported symptoms following a single dose administration on the day of dosing and up to the final visit 3-5 days later. Adverse events will be tabulated by total incidence and by individual patient, and the severity, causality and outcomes will also be documented. Each cohort of 4 patients will be fully evaluated as described before proceeding to the escalation to the next dose.</description>
          <population>Insufficient enrollment, therefore no Participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameters After a Single Dose of Inhaled Treprostinil and Acute Hemodynamic Effects.</title>
        <description>PK samples will be collected at frequent intervals up to 4 hours following single dosing . Hemodynamic parameters at 4 hours post dosing include heart rate, pulmonary arterial pressure, systemic arterial pressure, right atrial pressure, pulmonary capillary wedge pressure, mixed venous oxygen saturation and cardiac output.</description>
        <time_frame>acute</time_frame>
        <population>Insufficient enrollment, therefore no participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>18mcg Inhaled Treprostinil Cohort</title>
            <description>Number of participates on a dose of three 6mcg breaths (18mcg total)with Adverse Events</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameters After a Single Dose of Inhaled Treprostinil and Acute Hemodynamic Effects.</title>
          <description>PK samples will be collected at frequent intervals up to 4 hours following single dosing . Hemodynamic parameters at 4 hours post dosing include heart rate, pulmonary arterial pressure, systemic arterial pressure, right atrial pressure, pulmonary capillary wedge pressure, mixed venous oxygen saturation and cardiac output.</description>
          <population>Insufficient enrollment, therefore no participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>18mcg Inhaled Treprostinil Cohort</title>
          <description>Patients are to be divided in four cohorts of four patients each. The first cohort will receive a single dose of inhaled Treprostinil (18ug) and each subsequent cohort will receive increasing single doses of 36, 54 and 72ug.
Each patient will be evaluated on a screening visit (Visit 1) within 28 days prior to dosing, a confirmatory visit (Visit 2) within 14 days prior to dosing, a Baseline/Treatment/Post-Treatment visit( Visit 3) on the dosing day and a Follow-up Period (visit 4) for up to 5 days after dosing.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neck pain at cath site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was closed on December 31, 2009 and enrolled a total of 1 patient with complete assessment and 4 screened failures. The reason for the closure was lack of enrollment. No data will be analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rosa Negro-Vilar</name_or_title>
      <organization>Lung Rx</organization>
      <phone>240-821-1881</phone>
      <email>rnegrovilar@lungrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

